At baseline, patients included in the FLAURA study were required to have tumor tissue EGFR mutated advanced NSCLC, and to have blood samples for retrospective central Cobas plasma cfDNA analysis of the EGFR status. This evidence concerns the gene EGFR and non-small cell lung carcinoma.